首页> 外文OA文献 >Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

【2h】

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

机译：用于将非小细胞肺癌与先前用邻索替尼处理的EML4-ALK融合基因重复的蠕变inib：II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Daijiro Harada; Hideko Isozaki; Toshiyuki Kozuki; Toshihide Yokoyama; Hiroshige Yoshioka; Akihiro Bessho; Shinobu Hosokawa; Ichiro Takata; Nagio Takigawa; Katsuyuki Hotta; Katsuyuki Kiura;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial [J] . Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Thoracic cancer. . 2021,第5期

机译：用邻近治疗的EML4-ALK融合基因重复肾小序肾小序，以先前用邻接吲哚治疗：II期试验
2. MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) [J] . Young Kim, Toyoaki Hida, Hiroshi Nokihara, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：AL27.03 alectinib（ALC）与屈曲非小细胞肺癌（ALK + NSCLC）中的冰水序（CRZ）：III期研究的主要结果（J-ALEX）
3. MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) [J] . Young Kim, Toyoaki Hida, Hiroshi Nokihara, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：AL27.03 alectinib（ALC）与屈曲非小细胞肺癌（ALK + NSCLC）中的冰水序（CRZ）：III期研究的主要结果（J-ALEX）
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer [O] . Yen-Ting Lin, Yi-Nan Liu, Jin-Yuan Shih 2007

机译：临床因素，ALK融合变异和BIM多态性对克唑替尼治疗的晚期EML4–ALK重排非小细胞肺癌的影响
7. Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: a phase II global study [O] . Ou Sai-Hong Ignatius, Ahn Jin Seok, De Petris Luigi, 2016

机译：艾乐替尼治疗克唑替尼难治性重症非小细胞肺癌：II期全球研究

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

著录项

引文网络

相似文献

相关主题

期刊订阅